GSK Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by GSK Plc, dated November 21, 2022, serves as a transaction notification for the month of November 2022. The document discloses specific share transactions involving Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them, executed on the New York Stock Exchange.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It exclusively reports on individual share acquisition transactions. The specific transaction details are as follows:
- Instrument: American Depositary Shares (ADSs), ISIN: US37733W2044.
- Transaction Date: November 17, 2022.
- Transaction Price: $32.59 per ADS.
- Transaction Nature: Acquisitions resulting from dividend reinvestment plans.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely records routine, automated share acquisitions by executives via dividend reinvestment.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of insider trading activity compliant with securities regulations.
Key Facts for Investor Verification
- Dr. H. Barron (Non-Executive Director): Acquired 2,676.848 notional ADSs via the Executive Supplemental Savings Plan and 52.000 ADSs via the 401(k) plan.
- Mr. J. Ford (SVP and Group General Counsel): Acquired 49.810 notional ADSs via the Executive Supplemental Savings Plan.
- Transaction Source: All reported acquisitions were automatic reinvestments of dividends, not open-market purchases.
- Market Data: The transactions occurred at a price of $32.59 on the NYSE.